- Details
- Description
Packaging Size:
24t/Boxt
Strength:
5mg
Composition:
Chidamide (Tucidinostat)
Treatment:
Refractory peripheral T cell lymphoma (PTCL), T-cell leukemia-lymphoma (ATLL)
Form:
Tablet
Brand:
爱谱沙（Epidaza）
Quantity Unit:
5mg*24t/Box
Manufacturer:
Chipscreen Bioscences,Ltd.，china
Chidamide (also named Tucidinostat) is a histone deacetylase (HDAC) inhibitor that is used to treat various cancers, including relapsed or refractory peripheral T cell lymphoma (PTCL) and pancreatic cancer:
- Chidamide sold under the brand name 爱谱沙（Epidaza）® in china.
- Tucidinostat sold under the brand name Hiyasta ® in Japan.
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.
In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.
